Compare FKWL & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FKWL | QTTB |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.5M | 44.3M |
| IPO Year | 1997 | 2018 |
| Metric | FKWL | QTTB |
|---|---|---|
| Price | $3.54 | $6.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $13.00 |
| AVG Volume (30 Days) | 7.1K | ★ 231.8K |
| Earning Date | 02-17-2026 | 03-10-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | 94.12 | ★ 136.78 |
| EPS | 0.10 | ★ 2.42 |
| Revenue | $46,086,901.00 | ★ $53,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.14 | N/A |
| P/E Ratio | $35.80 | ★ $2.71 |
| Revenue Growth | ★ 49.65 | N/A |
| 52 Week Low | $3.52 | $1.38 |
| 52 Week High | $6.23 | $7.80 |
| Indicator | FKWL | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 35.44 | 67.97 |
| Support Level | $3.52 | $1.64 |
| Resistance Level | $4.28 | $7.80 |
| Average True Range (ATR) | 0.09 | 0.80 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 5.13 | 77.96 |
Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.